Expert Interview
Insights from Bristol Myers Squibb's CheckMate 816 Trial: Evaluating 5-Year Overall Survival Benefit with Neoadjuvant Nivolumab + Chemotherapy in Resectable NSCLC
Ticker(s): BMYInstitution: University of Colorado
- Medical Oncologist & Founding Director of the University of Colorado Cancer Center.
- Manages 50+ Patients with NSCLC
- Past president of the International Association for the Study of Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO); served as chairman of the FDA Oncology Drug Advisory Committee. Research focuses on novel molecular therapies and immunotherapies for lung cancer and other thoracic cancers.
How do you interpret the overall survival benefit observed at 5 years in the CheckMate 816 trial, and has it impacted your treatment approach for patients with resectable NSCLC?
Added By: sara_adminIn your clinical experience, which patient populations are the best candidates for neoadjuvant nivolumab plus chemotherapy, and are there any subgroups you’d approach with caution
Added By: sara_adminHave you seen any real-world differences in pathological complete response or long-term outcomes compared to what was observed in CheckMate 816?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
